Lyme disease (LD), anaplasmosis, babesiosis and other tick-borne diseases (TBDs) attributed to Ixodes ticks are thought to be widely underreported in the United States. To identify TBD cases diagnosed in 2009, but not reported to the Minnesota Department of Health (MDH), diagnostic and procedural billing codes suggestive of tick-borne diseases were used to select medical charts for retrospective review in medical facilities serving residents of a highly endemic county in Minnesota. Of 444 illness events, 352 (79%) were not reported.
View Article and Find Full Text PDFLarge commercial laboratories in the United States were surveyed regarding the number of specimens tested for eight tickborne diseases in 2008. Seven large commercial laboratories reported testing a total of 2,927,881 specimens nationally (including Lyme disease). Of these, 495,585 specimens (17%) were tested for tickborne diseases other than Lyme disease.
View Article and Find Full Text PDFBackground: Laboratory testing is helpful when evaluating patients with suspected Lyme disease (LD). A 2-tiered antibody testing approach is recommended, but single-tier and nonvalidated tests are also used. We conducted a survey of large commercial laboratories in the United States to assess laboratory practices.
View Article and Find Full Text PDFTick-borne diseases endemic to Minnesota include Lyme disease, babesiosis, anaplasmosis/ehrlichiosis, Powassan virus illness and Rocky Mountain spotted fever. Physicians need to be aware of these diseases and be vigilant about testing for them when patients present with acute febrile illness or rash within one month of potential tick exposure. In addition, they need to educate patients about these diseases and encourage prevention measures, especially use of tick repellents.
View Article and Find Full Text PDFCarditis can complicate Lyme disease in an estimated <5% of cases, but cardiogenic shock is rare. We report a case of severe biventricular heart failure as a manifestation of a Jarisch-Herxheimer reaction in a patient with early Lyme disease following treatment with ceftriaxone.
View Article and Find Full Text PDF